corsair capital management lp raised quintiles ims holdings inc q position by  million stock rose trending business market stock privacy policy corsair capital management lp raised quintiles ims holdings inc q position by  million stock rose july    by vivian currie investors sentiment increased to  in  q its up  from  in q it improved as  investors sold q shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  more from  million shares in q were reported huntington bank stated it has  of its portfolio in quintiles ims holdings inc nyseq copper rock prns ltd stated it has  shares or  of all its holdings state of new jersey common pension fund d a new jerseybased fund reported  shares comml bank of montreal can holds  of its portfolio in quintiles ims holdings inc nyseq for  shares glenview mgmt llc stated it has  of its portfolio in quintiles ims holdings inc nyseq calvert mngmt stated it has  in quintiles ims holdings inc nyseq corsair cap mgmt limited partnership stated it has  in quintiles ims holdings inc nyseq trust of vermont reported  shares oakworth cap accumulated  shares or  of the stock old mutual investors uk ltd holds  or  shares d e shaw holds  shares or  of its portfolio  million are owned by national bank of ny mellon fort washington advisors oh accumulated  shares or  of the stock robeco institutional asset management bv has  invested in quintiles ims holdings inc nyseq jennison associate llc reported m shares jay petschek increased its stake in quintiles ims holdings inc q by  based on its latest q regulatory filing with the sec corsair capital management lp bought  shares as the company’s stock rose  with the market the hedge fund run by jay petschek held  shares of the commercial physical  biological resarch company at the end of q valued at  million up from  at the end of the previous reported quarter corsair capital management lp who had been investing in quintiles ims holdings inc for a number of months seems to be bullish on the  billion market cap company the stock rose  or  reaching  per share about  shares traded quintiles ims holdings inc nyseq has risen  since july   and is uptrending it has outperformed by  the sp corsair capital management lp which manages about b and m us long portfolio decreased its stake in calpine corp nysecpn by  shares to  shares valued at m in q according to the filing it also reduced its holding in hd supply hldgs inc nasdaqhds by  shares in the quarter leaving it with  shares and cut its stake in news corp new nasdaqnwsa more recent quintiles ims holdings inc nyseq news were published by seekingalphacom which released “quintiles ims a novel way to invest in biopharma” on july   also nasdaqcom published the news titled “q crosses above average analyst target” on june   reuterscom‘s news article titled “quintiles ims explores sale of contract sales business sources” with publication date june   was also an interesting one quintiles ims holdings inc nyseq ratings coverage among  analysts covering quintiles transnational nyseq  have buy rating  sell and  hold therefore  are positive quintiles transnational had  analyst reports since july   according to sratingsintel avondale initiated the shares of q in report on wednesday october  with “sector weight” rating the stock of quintiles ims holdings inc nyseq has “market perform” rating given on thursday may  by wells fargo evercore downgraded the shares of q in report on wednesday may  to “hold” rating the stock of quintiles ims holdings inc nyseq earned “buy” rating by goldman sachs on wednesday october  jefferies maintained it with “hold” rating and  target in tuesday june  report ubs maintained the shares of q in report on wednesday october  with “buy” rating the rating was reinitiated by credit suisse with “outperform” on friday august  mizuho initiated quintiles ims holdings inc nyseq rating on tuesday december  mizuho has “neutral” rating and  target the firm earned “neutral” rating on friday december  by bank of america the company was maintained on thursday may  by mizuho receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter free email newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts analysts see  eps for liveperson inc lpsn eps for live oak bancshares inc lob expected at  analysts see  eps for legg mason inc lm eps for limelight networks inc llnw expected at  analysts see  eps for lumber liquidators holdings inc ll laboratory corp of america holdings lh analysts see  eps lear corporation lea analysts see  eps  eps expected for kapstone paper and packaging corp ks eps for kite realty group trust krg expected at   eps expected for kilroy realty corp krc get the next big winner in your inbox before the bell listsconsumer eagle should you buy quintiles ims holdings q ahead of earnings  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search should you buy quintiles ims holdings q ahead of earnings july    am edt by zacks equity research zackscom shutterstock photo investors are always looking for stocks that are poised to beat at earnings season and quintiles ims holdings incq may be one such company the firm has earnings coming up pretty soon and events are shaping up quite nicely for their reportthat is because quintiles ims holdingsis seeing favorable earnings estimate revision activity as of late which is generally a precursor to an earnings beat after all analysts raising estimates right before earningswith the most uptodate information possibleis a pretty good indicator of some favorable trends underneath the surface for q in this reportin fact the most accurate estimate for the current quarter is currently at  per share for q compared to a broader zacks consensus estimate of  per share this suggests that analysts have very recently bumped up their estimates for q giving the stock a zacks earnings esp of  heading into earnings seasonquintiles transitional holdings inc price and eps surprisequintiles transitional holdings inc price and eps surprise  quintiles transitional holdings inc quotewhy is this importanta positive reading for the zacks earnings esp has proven to be very powerful in producing both positive surprises and outperforming the market our recent  year backtest shows that stocks that have a positive earnings esp and a zacks rank  hold or better show a positive surprise nearly  of the time and have returned over  on average in annual returns see more top earnings esp stocks here given that q has a zacks rank  hold and an esp in positive territory investors might want to consider this stock ahead of earnings you can see  the complete list of todays zacks  rank strong buy stocks hereclearly recent earnings estimate revisions suggest that good things are ahead for quintiles ims holdings and that a beat might be in the cards for the upcoming reportmore stock news tech opportunity worth  billion in from driverless cars to artifical intelligence weve seen an unsurpassed growth of hightech products in recent months yesterdays sciencefiction is becoming todays reality despite all the innovation there is a single component no tech company can survive without demand for this critical device will reach  billion this year alone and its likely to grow even faster in the futurezacks has released a brandnew special report to help you take advantage of this exciting investment opportunity most importantly it reveals  stocks with massive profit potential  see these stocks now want the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free reportquintiles transitional holdings inc q free stock analysis reportto read this article on zackscom click herezacks investment research the views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of nasdaq inc this article appears in investing  earnings  investing ideas  stocks more from zackscom subscribe medtech stocks to top q estimates quintiles q oce software to simplify commercial functions quintiles ims holdings q holds secondary offering revised related earnings articles subscribe weyerhaeuser wy beats on q earnings lags on revenue   am kb home kbh up  since earnings report can it continue   am factset fds down  since earnings report can it rebound   am contributorzackscom equity research follow on most popular highest rated mitel to acquire shoretel  quick facts sientra completes acquisition of miramar labs® seagate technology plc q profit rises  ledgerx gets us approval for derivatives on digital currencies us fines frontier american and delta for violating consumer shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results spectranetics announces fda approval of stellarex™ drugcoated balloon view all highest rated research brokers before you trade compare online brokers want to trade fx visit our forex broker center  find a credit card select a credit card product by  card type  credit score  card issuer select an offer  apr credit cardsairline credit cardsbalance transfer credit cardsbusiness credit cardscash back credit cardscharge cardscharge cards for businessemv smart chipsgas cards  auto rewardshome improvement rewards credit cardsinstant approval credit cardslow interest credit cardsno annual fee credit cardsno foreign transaction fee credit cardspoints rewards credit cardsprepaid  debit cardsreward credit cardsstudent credit cardstop  best credit card deals and offers bad creditcredit quality averagecredit quality excellentcredit quality faircredit quality goodlimited or no credit historypersonal loans american expressamerican express airline cardsamerican express business cardsamerican express cash back credit cardsamerican express charge cardsbarclaycardcapital onecapital one cash backcapital one fair creditcapital one milescapital one pointscapital one prepaid credit cardschaseciti credit cardsdiscoverdiscover cashbackdiscover milesdiscover student credit cardsmastercard credit cardsus bankusaausaa savingsvisa credit cards search data provided by bankratecom stocks referenced q  rate it closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex should you buy quintiles ims holdings q ahead of earnings  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search should you buy quintiles ims holdings q ahead of earnings july    am edt by zacks equity research zackscom shutterstock photo investors are always looking for stocks that are poised to beat at earnings season and quintiles ims holdings incq may be one such company the firm has earnings coming up pretty soon and events are shaping up quite nicely for their reportthat is because quintiles ims holdingsis seeing favorable earnings estimate revision activity as of late which is generally a precursor to an earnings beat after all analysts raising estimates right before earningswith the most uptodate information possibleis a pretty good indicator of some favorable trends underneath the surface for q in this reportin fact the most accurate estimate for the current quarter is currently at  per share for q compared to a broader zacks consensus estimate of  per share this suggests that analysts have very recently bumped up their estimates for q giving the stock a zacks earnings esp of  heading into earnings seasonquintiles transitional holdings inc price and eps surprisequintiles transitional holdings inc price and eps surprise  quintiles transitional holdings inc quotewhy is this importanta positive reading for the zacks earnings esp has proven to be very powerful in producing both positive surprises and outperforming the market our recent  year backtest shows that stocks that have a positive earnings esp and a zacks rank  hold or better show a positive surprise nearly  of the time and have returned over  on average in annual returns see more top earnings esp stocks here given that q has a zacks rank  hold and an esp in positive territory investors might want to consider this stock ahead of earnings you can see  the complete list of todays zacks  rank strong buy stocks hereclearly recent earnings estimate revisions suggest that good things are ahead for quintiles ims holdings and that a beat might be in the cards for the upcoming reportmore stock news tech opportunity worth  billion in from driverless cars to artifical intelligence weve seen an unsurpassed growth of hightech products in recent months yesterdays sciencefiction is becoming todays reality despite all the innovation there is a single component no tech company can survive without demand for this critical device will reach  billion this year alone and its likely to grow even faster in the futurezacks has released a brandnew special report to help you take advantage of this exciting investment opportunity most importantly it reveals  stocks with massive profit potential  see these stocks now want the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free reportquintiles transitional holdings inc q free stock analysis reportto read this article on zackscom click herezacks investment research the views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of nasdaq inc this article appears in investing  earnings  investing ideas  stocks more from zackscom subscribe medtech stocks to top q estimates quintiles q oce software to simplify commercial functions quintiles ims holdings q holds secondary offering revised related earnings articles subscribe weyerhaeuser wy beats on q earnings lags on revenue   am kb home kbh up  since earnings report can it continue   am factset fds down  since earnings report can it rebound   am contributorzackscom equity research follow on most popular highest rated mitel to acquire shoretel  quick facts sientra completes acquisition of miramar labs® seagate technology plc q profit rises  ledgerx gets us approval for derivatives on digital currencies us fines frontier american and delta for violating consumer shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results spectranetics announces fda approval of stellarex™ drugcoated balloon view all highest rated research brokers before you trade compare online brokers want to trade fx visit our forex broker center  find a credit card select a credit card product by  card type  credit score  card issuer select an offer  apr credit cardsairline credit cardsbalance transfer credit cardsbusiness credit cardscash back credit cardscharge cardscharge cards for businessemv smart chipsgas cards  auto rewardshome improvement rewards credit cardsinstant approval credit cardslow interest credit cardsno annual fee credit cardsno foreign transaction fee credit cardspoints rewards credit cardsprepaid  debit cardsreward credit cardsstudent credit cardstop  best credit card deals and offers bad creditcredit quality averagecredit quality excellentcredit quality faircredit quality goodlimited or no credit historypersonal loans american expressamerican express airline cardsamerican express business cardsamerican express cash back credit cardsamerican express charge cardsbarclaycardcapital onecapital one cash backcapital one fair creditcapital one milescapital one pointscapital one prepaid credit cardschaseciti credit cardsdiscoverdiscover cashbackdiscover milesdiscover student credit cardsmastercard credit cardsus bankusaausaa savingsvisa credit cards search data provided by bankratecom stocks referenced q  rate it closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex quintiles ims holdings q holds secondary offering revised  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search quintiles ims holdings q holds secondary offering revised june    pm edt by zacks equity research zackscom shutterstock photo leading provider of product development and integrated healthcare services quintiles ims holdings inc q held a secondary offering of m shares of which they repurchased m worth stock performance in the last three months quintiles shares have increased roughly  against the zacks categorized medical services subindustrys loss of  the current level is higher than the sp s return of  over the same time frame finally a longterm expected earnings growth rate of  instills confidence in investors the estimate revision for the stock has been unfavorable the current quarter has seen seven estimates move south over the last month compared with one movement in the opposite direction as a result earnings estimates for the current quarter have declined  cents to  over the same period quintiles carries a zacks rank  hold the transaction is expected to close on may   subject to customary closing conditions the company expects to fund the repurchase with cash on hand and borrowings from its revolving credit facility as of mar   the company had  million of cash and cash equivalents in its books looking forward we believe inorganic expansion has acted as a major catalyst for the company the strategic alliance with davita clinical research a wholly owned subsidiary of davita healthcare is a notable development from this transaction quintiles is expected to gain nephrology expertise and enhance its global delivery capabilities which will fortify its position in the field of clinical research the company has  years of experience in the field of clinical trial research especially in therapeutics the launch of continuous glucose monitoring service is a major growth driver for quintiles notably the solution offers innovative and wearable technology for diabetesfocused clinical trials which is highly exclusive in the market in this regard a report by markets and markets forecasts that the global market for glucose dextrose and maltodextrin is projected to reach a worth of  billion by  at a cagr of  key picks betterranked stocks in the broader medical sector include luminex corporation lmnx  edwards lifesciences corp ew and inogen inc ingn  inogen and luminex sport a zacks rank  strong buy while edwards lifesciences carries a zacks rank  buy you can see  the complete list of todays zacks  strong buy rank stocks here  inogen projects a longterm adjusted earnings growth of almost  the stock returned  over the last one year luminex has an expected longterm adjusted earnings growth of almost  the stock added roughly  over the last three months edwards lifesciences has a longterm expected earnings growth rate of  the stock has a solid oneyear return of roughly  more stock news  companies verge on applelike run  did you miss apples x stock explosion after they launched their iphone in  now  looks to be a pivotal year to get in on another emerging technology expected to rock the market demand could soar from almost nothing to  billion by  reports suggest it could save  million lives per decade which could in turn save  billion in us healthcare costs a bonus zacks special report names this breakthrough and the  best stocks to exploit it like apple in  these companies are already strong and coiling for potential megagains click to see them right now  we are reissuing this article to correct a mistake the original article issued may   should no longer be relied upon want the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free report quintiles transitional holdings inc q free stock analysis report luminex corporation lmnx free stock analysis report inogen inc ingn free stock analysis report edwards lifesciences corporation ew free stock analysis report to read this article on zackscom click here zacks investment research the views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of nasdaq inc this article appears in investing  business  stocks referenced symbols q  lmnx  ingn  ew more from zackscom subscribe medtech stocks to top q estimates should you buy quintiles ims holdings q ahead of earnings quintiles q oce software to simplify commercial functions related stocks articles subscribe eagle materials inc cements another record for revenue thanks to an acquisition   am european stocks follow asia lower on technology rout amazon earnings miss   am how ford found a tax break to offset a profit drop   am contributorzackscom equity research follow on most popular highest rated mitel to acquire shoretel  quick facts sientra completes acquisition of miramar labs® seagate technology plc q profit rises  ledgerx gets us approval for derivatives on digital currencies us fines frontier american and delta for violating consumer shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results spectranetics announces fda approval of stellarex™ drugcoated balloon view all highest rated research brokers before you trade compare online brokers want to trade fx visit our forex broker center  find a credit card select a credit card product by  card type  credit score  card issuer select an offer  apr credit cardsairline credit cardsbalance transfer credit cardsbusiness credit cardscash back credit cardscharge cardscharge cards for businessemv smart chipsgas cards  auto rewardshome improvement rewards credit cardsinstant approval credit cardslow interest credit cardsno annual fee credit cardsno foreign transaction fee credit cardspoints rewards credit cardsprepaid  debit cardsreward credit cardsstudent credit cardstop  best credit card deals and offers bad creditcredit quality averagecredit quality excellentcredit quality faircredit quality goodlimited or no credit historypersonal loans american expressamerican express airline cardsamerican express business cardsamerican express cash back credit cardsamerican express charge cardsbarclaycardcapital onecapital one cash backcapital one fair creditcapital one milescapital one pointscapital one prepaid credit cardschaseciti credit cardsdiscoverdiscover cashbackdiscover milesdiscover student credit cardsmastercard credit cardsus bankusaausaa savingsvisa credit cards search data provided by bankratecom stocks referenced q  rate it lmnx  rate it ingn  rate it ew  rate it closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex quintiles ims holdings inc q company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile quintiles ims holdings inc q related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse q on new york consolidated usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description quintiles ims holdings inc formerly quintiles transnational holdings inc incorporated on october   provides integrated information and technologyenabled healthcare services the company operates through segments including commercial solutions research  development solutions and integrated engagement services it serves pharmaceutical biotechnology medical device and healthcare companies the company has its operations in the americas europe and africa and the asiapacificcommercial solutionsthe commercial solutions segment offerings include national information offerings subnational information offerings technology solutions and workflow analytics and consulting services the company provides country level performance metrics related to sales of pharmaceutical products prescribing trends medical treatment and promotional activity across multiple channels including retail hospital and mail order these solutions are an integral part of processes in life science companies around the world and are also used by the investment and financial sectors that deal with life science companies it also provides a measurement of sales or prescribing activity at the regional zip code and individual prescriber level depending on regulation in the relevant country as of december   its reference database tracked over  million healthcare professionals in over  countries providing a view of healthcare practitionersthe company enables clients to use patientlevel data to understand treatments outcomes and costs to inform and advance healthcare decision making with patient privacy and security safeguards it offers data assets that integrate medical claims prescriptions electronic medical records biomarkers and government statistics as needed for research requirements it provides a range of cloudbased applications and associated implementation services softwareasaservice saas solutions support a range of commercial and regulatory processes including multichannel marketing customer relationship management crm performance management incentive compensation territory alignment roster management call planning compliance reporting and master data management these solutions are used by healthcare companies to manage optimize and execute their commercial strategies in an orchestrated manner while addressing their regulatory obligations as of december   using algorithms the company combined its countrylevel data healthcare expertise and therapeutic knowledge in over  countries to create its global market insight family of offerings such as midas analytics link and disease insights it provides a set of consulting services including analytics and commercial processes outsourcing servicesresearch  development solutionsthe research  development solutions segment provides biopharmaceutical development services it offers project management and clinical monitoring clinical trial support services q solutions and strategic planning and design its clinical solutions and services service offerings include protocol design feasibility and operational planning site start up and patient recruitment it offers a range of functional services and consultation to support clinical trials through specialized expertise that help clients collect analyze and report the quality data and evidence they need to gain regulatory approval it provides its clients globally scaled endtoend clinical trial laboratory and research services it offers clinical trial genomic and bioanalytical laboratory service offerings within the joint venture which is referred to as q solutions through its strategic planning and design services it offers consultation servicesintegrated engagement servicesthe integrated engagement services segment offerings include healthcare provider engagement services patient engagement services and scientific strategy and medical affairs services its patient engagement services combine insight from clinical trials and social listening behavioral design personal and ehealth multichannel interactions across multiple sites such as the physicians office hospital pharmacy home the company partners with biopharmaceutical companies and other life sciences providers such as medical device companies to develop and deploy stakeholder engagement solutions including contract sales and market access professionalsthe company competes with accenture cognizant technology solutions covance inc deloitte evidera gfk lexisnexis risk solutions ibm infosys inventiv health inc kantar health mckinsey nielsen nv optuminsight parexel international corporation inc press ganey rti health solutions symphony health solutions synovate healthcare the advisory board trizetto veeva verisk analytics inc zs associates pharmaceutical product development inc parexel international corporation icon plc inc research holdings pra international laboratory corporation of america holdings united drug plc eps corporation and cmic holdings co ltd » full overview of q company address quintiles ims holdings inc  emperor blvddurham   nc    p f  company web links home page officers  directors name compensation ari bousbib  thomas pike  michael mcdonnell  kevin knightly  james erlinger  » more officers  directors quintiles ims holdings inc news eqt to acquire pharmaceutical services firm certara jul   update eqt to acquire pharmaceutical services firm certara jul   quintiles ims explores sale of contract sales business sources jun   quintiles ims explores sale of contract sales business sources jun   briefquintiles ims holdings files for potential stock shelf may   » more q news related topics stocksstock screenerhealthcarebiotechnology  medical research data dumps    freebase api deprecated    google developers freebase api deprecated all products sign in send feedback hey there are you maybe looking for firebase instead data dumps the freebase api will be completely shutdown on aug   this page provides access to the last available data dump read more data dumps are a downloadable version of the data in freebase they constitute a snapshot of the data stored in freebase and the schema that structures it and are provided under the same ccby license the freebasewikidata mappings are provided under the cc license freebase triples freebase deleted triples freebasewikidata mappings license citing freebase triples this dataset contains every fact currently in freebase total triples  billion updated weekly data format ntriples rdf license ccby  gb gzip gb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagedate httpwwwworgxmlschemagyearmonth  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagesource httprdffreebasecomnsgxgfm  httprdffreebasecomnsgvjzynm httprdffreebasecomnstypeobjecttype httprdffreebasecomnsmeasurementunitdatedpercentage  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagerate   httprdffreebasecomnsgvjzynm httpwwwworgrdfsyntaxnstype httprdffreebasecomnsmeasurementunitdatedpercentage  if youre writing your own code to parse the rdf dumps its often more efficient to read directly from gzip file rather than extracting the data first and then processing the uncompressed data subject predicate object  note in freebase objects have mids that look like mrkqx in rdf those mids become mrkqx likewise freebase schema like commontopic are written as commontopic the subject is the id of a freebase object it can be a freebase mid ex mrkqx for topics and cvts or a humanreadable id ex commontopic for schema the predicate is always a humanreadable id for a freebase property or a property from a standard rdf vocabulary like rdfs freebase foreign key namespaces are also used as predicates to make it easier to look up keys by namespace the object field may contain a freebase mid for an object or a humanreadable id for schema from freebase or other rdf vocabularies it may also include literal values like strings booleans and numeric values topic descriptions often contain newlines in order to make each triple fit on one line we have escaped newlines with n freebase deleted triples we also provide a dump of triples that have been deleted from freebase over time this is a onetime dump through march  in the future we might consider providing periodic updates of recently deleted triples but at the moment we have no specific timeframe for doing so and are only providing this onetime dump the dump is distributed as a targz file gb compressed gb uncompressed it contains  deleted triples in  files there is no particular meaning to the individual files it is just easier to manipulate several smaller files than one huge file thanks to chun how tan and john giannandrea for making this data release possible total triples  million updated june   data format csv license ccby  gb gzip gb uncompressed download the data format is essentially csv with one important caveat the object field may contain any characters including commas as well as any other reasonable delimiters you could think of however all the other fields are guaranteed not to contain commas so the data can still be parsed unambiguously the columns in the dataset are defined as creationtimestamp unix epoch time in milliseconds creator deletiontimestamp unix epoch time in milliseconds deletor subject mid predicate mid object midliteral languagecode csv usermwclwikipediaenusermwclwikipediaenmrtypeobjectkeywikipediaenben usermwclmusicbrainzuserturtlewaxbotmnncpzmusicrecordingartistmvbfmen usermwclimagesusergardeningbotmwmcommonimagesizemklyen usermwclmusicbrainzusermbzpipelinemergebotmfvvltypeobjecttypecommontopicen usermwclimagesusergardeningbotmxsczcommonlicensedobjectlicensemxben usercontentadministratorusergardeningbotmgkbytypeobjecttypetypecontenten usermwclimagesusergardeningbotmhcommontopicimagemcsen usermwclchefmozuserdeletebotmzcztypeobjectnamela casa rosa mexican restauranten freebasewikidata mappings the data has been created based on the wikidatadump of october   and contains only those links that have at least two common wikipedialinks and not a single disagreeing wikipedialink furthermore the lines are sorted by the number of common wikipedialinks although in turtle this does not really matter total triples m updated october   data format ntriples rdf license cc  mb gzip mb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsmj httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmnrg httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmjgd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmgd httpwwwworgowlsameas httpwwwwikidataorgentityq  license freebase data dumps are provided free of charge for any purpose with regular updates by google they are distributed like freebase itself under the creative commons attribution aka ccby and use is subject to the terms of service the freebasewikidata id mappings are provided under cc and can be used without restrictions citing if youd like to cite these data dumps in a publication you may use google freebase data dumps httpsdevelopersgooglecomfreebasedata month day year or as bibtex bibtex misc except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel quintilesims  wikipedia quintilesims from wikipedia the free encyclopedia jump to navigation search for quintiles the statistical distribution grouping into fifths see quantile quintiles ims holdings inc type public traded as nyse q russell  component industry contract research organization pharmaceutical service consulting founded  headquarters durham north carolina usa key people dennis gillings founder ari bousbib chairman and ceo products support services for pharmaceutical biotech and medical companies and individuals revenue us  billion  number of employees    website httpwwwquintilesimscom quintiles ims holdings inc branded as quintilesims is an american multinational company serving the combined industries of health information technologies and clinical research it is a fortune  company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than  employees conducting business in approximately  countries quintilesims is the world’s largest contract research organization as ranked by reported service revenues and is focused primarily on phase iiiv clinical trials and associated laboratory and analytical services historyedit in  dennis gillings founded and incorporated quintiles transnational in north carolina quintiles transnational established quintiles pacific inc and quintiles ireland ltd in  and in  quintiles gmbh was established in germany and quintiles laboratories ltd was established in atlanta georgia in september  quintiles purchased innovex ltd of britain for  million in stock quintiles went public in  and completed a successful secondary stock offering over  concluding on october  quintiles underwent a  billion merger with ims health becoming quintilesims referencesedit  fortune   a b c smith rick quintiles ims health complete b merger no word on any job cuts wral techwire capitol broadcasting corporation inc retrieved    inside quintiles the worlds largest cro outsourcingpharmacom   matthew herper november   money math and medicine forbes magazine retrieved july     quintiles pacific inc private company information  businessweek   quintiles laboratories limited private company information  businessweek   derdak t atkins w  quintiles transnational corp encyclopediacom cs maint uses authors parameter link  olivia oran  may  quintiles ipo raises morethanplanned  million as stocks rally reuters   henderson jennifer  october  quintiles ims health complete merger triangle business journal american city business journals retrieved  october   external linksedit quintilesims website retrieved from httpsenwikipediaorgwindexphptitlequintilesimsoldid categories companies listed on the new york stock exchangecompanies based in reading berkshirecompanies based in durham north carolinacompanies based in north carolina by citycontract research organizationscompanies established in life sciences industry establishments in north carolina initial public offeringscompanies formed by mergerhidden categories cs maint uses authors parameter navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages italianoрусский edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view quintilesims quintilesims  twitter skip to content home home home current page moments moments moments current page search query search twitter saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어 語   have an account log in have an account remember me · forgot password new to twitter sign up quintilesims quintilesims tweets tweets current page  following following  followers followers  likes likes  lists lists    more likes lists unmute quintilesims mute quintilesims follow following unfollow blocked unblock pending cancel quintilesims quintilesims solutions for you to drive healthcare forward we provide clients an opportunity to realize full potential of innovation  advance healthcare outcomes quintilesimscom joined may   photos and videos photos and videos tweets tweets tweets current page tweets  replies media you blocked quintilesims are you sure you want to view these tweets viewing tweets wont unblock quintilesims yes view profile close quintilesims followed quintilesims‏ quintilesims h hours ago more copy link to tweet embed tweet want to work in durham nc view our latest opening httpbitlytddok  marketing job jobs hiring careerarc  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims h hours ago more copy link to tweet embed tweet otc product sales now represent more than  of total pharma industry revenues learn more httpbitlywme pictwittercomenaiggtnu  replies  retweets  likes reply  retweet  retweeted  like liked thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims h hours ago more copy link to tweet embed tweet biosimilars could generate billions for the us market download to learn more httpbitlytnfym pictwittercomdqxkbpkjb  replies  retweets  like reply retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims h hours ago more copy link to tweet embed tweet find out how wellness trends and emerging markets growth are boosting sales in overthecounter products httpbitlyuopck  otcpictwittercomutzwqk  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims h hours ago more copy link to tweet embed tweet plunge into summer and stay in top form download our  pearls of market access wisdom httpbitlytmiuxs  lifesciencespictwittercomoiaygru  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims h hours ago more copy link to tweet embed tweet we are hiring cras brian constance is a clinicalresearch associate and participated in this program more infohttpbitlyvoxd   replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet the business case for patienteducation httpbitlyuywtqm pictwittercomkahcuqekq  replies  retweets  like reply retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet learn how patienteducation can support clinicalresearch recruitment and retention httpbitlyucdwn pictwittercommczryad  replies  retweets  like reply retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet susan harris  chris kelly explain the business case for providing patienteducation httpbitlyuwxemk  clinicalresearch adherencepictwittercomwkvbrpvryy  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet unprecedented innovation is reshaping the world of oncology derive insights and understand trends in cancer carehttpbitlytjamp   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet want to work at quintilesims were hiring in durham nc click for details httpbitlysvwpk  marketing job jobs careerarc  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet research forum showcases groundbreaking studies using rwd that aid public policy decisions  treatment protocols httpbitlytahrb pictwittercomvbgihooaak  replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet what it takes to thrive in an increasingly specialized marketplace httpbitlytwfezx  launchexcellencepictwittercomwjbfgkqrs  replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet solving public health challenges with realworld data httpbitlyutevph  rwd rwepictwittercomnkfeenrc  replies  retweets  like reply retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet were hiring janine scott talks about why she chose to work for a leader in the healthcare industryhttpbitlytvxib   replies  retweets  like reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet top  takeaways from the asco annual meeting httpbitlytvrtkl  asco oncology  replies  retweet  likes reply retweet  retweeted  like liked thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet with patent expirations looming biologic companies must innovate – or litigate – to protect their market share httpbitlytwso pictwittercomhpyfktai  replies  retweets  like reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet learn the  key drivers for pharma to provide patientcentric programs httpbitlyuqptib  patientsupportpictwittercomjvkffdmd  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet discover how to support the patient journey by engaging patients with healthcare decisions httpbitlyttqz  patientcentricpictwittercomxzrhtlqqg  replies  retweets  like reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo quintilesims‏ quintilesims jul  more copy link to tweet embed tweet john procter and peter rutherford discuss maximizing patientengagement to improve patient outcomes httpbitlyupypex pictwittercomjtbyjlewvn  replies  retweet  likes reply retweet  retweeted  like liked thanks twitter will use this to make your timeline better undo quintilesims hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user contact us  quintilesims menu about us investor relations services therapeutics insights careers events  webinars investigators global markets contact us our focus our history awards  recognition sustainability ethics  compliance news media contacts modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines about us our focus our history awards  recognition sustainability ethics  compliance news media contacts investor relations services advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology therapeutics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines insights careers events  webinars investigators global markets contact us home contact us contact us general contact information sales and corporate support   us tollfree in country  for international calls please find a number in our tollfree list corporate headquarters   us tollfree only  for international calls please find a number in our tollfree list global locations select country for contact details argentina australia austria belgium brazil bulgaria canada chile china colombia croatia czech republic denmark egypt estonia finland france germany ghana greece guatemala hong kong hungary india indonesia ireland israel italy japan kenya latvia lithuania malaysia malta mexico netherlands new zealand poland portugal romania russia serbia singapore slovakia south africa south korea spain sweden switzerland taiwan thailand turkey ukraine united kingdom united states vietnam support and resources customers contact our sales team request an rfprfi quintiles infosario portal clinical trial support infosario support team anytime access qecg web site quintiles contact center media relations media contacts list request an interview careers quintiles careers search for opportunities by region employees connect iq other contact information contact sales request an rfp investigator recruiting opportunities selfservice registration patient recruitment infosario support general questions about quintilescom at quintilesims we conduct our business within the framework of applicable professional standards laws regulations and internal policies should you have any questions or concerns regarding business conduct please contact the business ethics office locations  quintilesims menu about us investor relations services therapeutics insights careers events  webinars investigators global markets contact us our focus our history awards  recognition sustainability ethics  compliance news media contacts modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines about us our focus our history awards  recognition sustainability ethics  compliance news media contacts investor relations services advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology therapeutics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines insights careers events  webinars investigators global markets contact us home locations × statename operating since operatingsince go to statename  north america canada united states asia china hong kong india indonesia israel japan malaysia philippines singapore south korea taiwan thailand vietnam australia  new zealand australia new zealand europe austria belgium bulgaria croatia czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania malta netherlands poland portugal romania russia serbia slovakia spain sweden switzerland turkey ukraine united kingdom latin america argentina brazil chile colombia guatemala mexico middle east  africa egypt ghana kenya south africa quintiles careers  quintilesims menu about us investor relations services therapeutics insights careers events  webinars investigators global markets contact us our focus our history awards  recognition sustainability ethics  compliance news media contacts modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines about us our focus our history awards  recognition sustainability ethics  compliance news media contacts investor relations services advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology therapeutics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines insights careers events  webinars investigators global markets contact us home quintiles careers quintiles careers connect to great opportunity™ – there is no limit to what you can achieve here working alongside smart and driven colleagues you can make a lasting impact on our customers the industry patient health around the world and your career careers who youll work for who youll work with what youll do featured job cra careers who youll work for who youll work with what youll do featured job cra worldwide opportunities from entrylevel candidates to seasoned professionals quintiles hires talent across a multitude of business functions whether your passion is corporate support clinical drug development customer engagement or sales – you can follow a defined career path or create your own search for career opportunities in your region below apply online     visit our local country pages below to learn more about working at quintiles search jobs by location select country argentina australia austria belgium brazil bulgaria canada chile china colombia croatia czech republic denmark egypt estonia france germany ghana greece guatemala hong kong hungary india indonesia ireland israel italy japan latvia lithuania malaysia malta mexico netherlands new zealand poland portugal romania russia serbia singapore slovakia south africa south korea spain sweden switzerland taiwan thailand turkey ukraine united kingdom united states vietnam equal employment opportunity and affirmative action quintilesims provides equal opportunity in all employment decisions such as compensation benefits transfers leaves returns from leave companysponsored training education education reimbursement and social and recreational programs for all qualified applicants and team members without regard to race color gender national origin religion age sexual orientation gender identity genetic information physical or mental disability pregnancy marital status status as a protected veteran or any other status protected by federal state or local law quintilesims recruits hires trains and promotes people in all job titles without regard to race color gender national origin religion age sexual orientation gender identity genetic information physical or mental disability pregnancy marital status status as a protected veteran or any other status protected by federal state or local law quintilesims promotes effective use of all team members protected veterans minorities women and those with disabilities among them through a positive continuing affirmative action program at all levels throughout the company relevant military experience is considered for veterans and transitioning service men and women  quintilesims is an affirmative action and equal opportunity employer minorityfemaledisabledveterangender identitysexual orientation fraud alert quintilesims has zero tolerance for fraud and deception in the employment marketplace while we use various methods to communicate with prospective employees we do not interview candidates online or via text messages nor do we ever request payment of any kind as a condition of employment if you have been contacted online or through a text message by anyone representing themselves as being from quintilesims and are concerned about their legitimacy please make us aware immediately inform us connect with quintiles talent network facebook linkedin twitter quintiles recent awards quintiles india was honored in the bio excellence awards for outstanding achievements in biotechnology recognized as one of the best multinational workplaces in europe other  honors include germany italy poland spain and the united kingdom and previously recognized in ireland netherlands and scotland earned britain’s healthiest company of the year honors in  and  selected in all five categories of quality reliability regulatory productivity and innovation for the  life science leader leadership award recognized with a computerworld data editor’s choice award for its infosario technology platform quintiles ims holdings inc private company information  bloomberg july    am et life sciences tools and services company overview of quintiles ims holdings inc snapshot people company overview quintiles ims holdings inc provides integrated information and technologyenabled healthcare services in the americas europe africa and the asiapacific it operates through three segments commercial solutions research  development solutions and integrated engagement services the commercial solutions segment offers country level performance metrics related to sales of pharmaceutical products prescribing trends medical treatment and promotional activity across various channels including retail hospital and mail order to life science companies and investment and financial sectors that deal with life science companies and measurement of sales or prescribing activity at the reg quintiles ims holdings inc provides integrated information and technologyenabled healthcare services in the americas europe africa and the asiapacific it operates through three segments commercial solutions research  development solutions and integrated engagement services the commercial solutions segment offers country level performance metrics related to sales of pharmaceutical products prescribing trends medical treatment and promotional activity across various channels including retail hospital and mail order to life science companies and investment and financial sectors that deal with life science companies and measurement of sales or prescribing activity at the regional zip code and individual prescriber level to pharmaceutical sales organizations this segment also provides onekey a reference database of healthcare professionals realworld insights and various cloudbased applications and related implementation services and strategic and implementation consulting services including advanced analytics and commercial processes outsourcing services the research  development solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring clinical trial support and strategic planning and design services as well as clinical trial genomic and bioanalytical laboratory services the integrated engagement services segment provides health care provider and patient engagement services and scientific strategy and medical affairs services quintiles ims holdings inc serves pharmaceutical biotechnology medical device and healthcare companies the company was formerly known as quintiles transnational holdings inc and changed its name to quintiles ims holdings inc as a result of its merger with ims health holdings inc in october  the company was founded in  and is headquartered in durham north carolina detailed description  emperor boulevarddurham nc united statesfounded in  employees phone  wwwquintilesimscom key executives for quintiles ims holdings inc mr ari bousbib chairman chief executive officer and president age  total annual compensation k mr michael r mcdonnell cpa chief financial officer and executive vice president age  total annual compensation m mr w richard staub iii president of research  development solutions business unit age  total annual compensation k mr kevin c knightly president of information and technology solutions age  total annual compensation k mr james h erlinger iii executive vice president general counsel and secretary age  total annual compensation k compensation as of fiscal year  quintiles ims holdings inc key developments quintilesims appointments colleen goggins to its board of directors jul   quintilesims announced the appointment of colleen goggins to its board of directors effective july   a senior executive at johnson  johnson for more than three decades goggins retired in  after serving ten years on jj’s executive committee and as the worldwide chairman of its consumer group goggins is a member of the supervisory board of bayer ag and a member of the board of directors of td bank group goggins is also a member of the university of wisconsin foundation and serves on the boards of directors of the university of wisconsin center for brand and product management the child health institute of new jersey the institute of international education and new york city mealsonwheels veeva systems files suit in california against medidata quintilesims and sparta for employment clauses jul   veeva systems said it has filed suit in the superior court of california against three companies medidata quintilesims and sparta the suit alleges the companies used illegal provisions in their employment agreements including posttermination noncompetes and overly broad confidentiality and nondisparagement clauses quintilesims announces new responsibilities to tim sheppard general manager jul   quintilesims has announced that tim sheppard general manager has taken on new responsibilities which will see him lead the quintilesims engagement with uk regulators government and industry bodies following the merger of quintiles and ims health last year sheppard will oversee the evolution of a unified company culture and will also facilitate collaboration across its broad range of capabilities while also leading on ongoing integration activities sheppard has worked at quintilesims since  when he joined as general manager for ims health uk and ireland prior to joining the company he led the healthcare sector at unipart expert practice and served as director of the public sector for dell services among various other roles similar private companies by industry company name region x genomics inc united states g clinical inc united states aapharmasyn llc united states abiant inc united states abiobot inc united states recent private companies transactions typedate target mergeracquisition august    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact quintiles ims holdings inc please visit wwwquintilesimscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close login page  quintilesims menu about us investor relations services therapeutics insights careers events  webinars investigators global markets contact us our focus our history awards  recognition sustainability ethics  compliance news media contacts modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines about us our focus our history awards  recognition sustainability ethics  compliance news media contacts investor relations services advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology therapeutics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines insights careers events  webinars investigators global markets contact us home log in to other quintiles web sites customers anytime access quintiles infosario portal clinical trial support infosario qecg web site jobseekers  candidates   start your job search at quintilescomcareers employees only iq connect cro clinical trial services pharmaceutical consulting  quintilesims menu about us investor relations services therapeutics insights careers events  webinars investigators global markets contact us our focus our history awards  recognition sustainability ethics  compliance news media contacts modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines about us our focus our history awards  recognition sustainability ethics  compliance news media contacts investor relations services advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology therapeutics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines insights careers events  webinars investigators global markets contact us solutions for you to drive healthcare forward quintiles and imshealth have merged to form quintilesims find out more who we are about us news featured services precision medicine riskbased monitoring oncology realworld  late phase strategy market access advisory services how we think blog authors peerreviewed publications library events  webinars tradeshows webinars quintiles service emerging biopharma quintiles service emerging biopharma specific needs arise from operating and leading a small organization–getting to your next milestone ensuring funding delivering studies while managing resource constraints and launch planning just to name a few the future of your programs your company and the practitioners and patients you are aiming to help are all at stake by offering personalized attention and global therapeutic expertise quintilesims can help you confidently create and deliver the right evidence generation plan and optimize your asset value emerging biopharmaclinical developmentplanning and designmarket access and commercialization fact sheet solutions for emerging biopharma presentation strategic considerations for clinical development programs in emerging biopharma companies presentation optimizing realworld evidence programs to generate value your request for information or proposal area of interest access to patients clinical services clinical trials commercial services consulting services early clinical development late phase services quintiles infosario regulatory services   quintiles solutions clinical development quintiles solutions clinical development transform clinical development by connecting healthcare data new technologies advanced methodologies and scientific expertise together these resources increase your understanding of how patients are treated and which sites have the potential targeted population they also help provide understanding around what clinical outcomes lead to commercial success and offer realworld information to help you confidently value your advancements riskbased monitoringrare disease oncologyinsights on clinical developmentprecision enrollment for sites white paper riskbased monitoring improves site performance and investigator satisfaction infographic tailored solution for rare disease studies white paper transforming patient recruitment through patient and site engagement quintiles careers join us and get the satisfaction of doing great work that matters we are looking for talented professionals who share our values and passion to create a healthier world we are the industry leader and can provide you with the tools and resources needed to succeed and offer great career path opportunities erica briody vice president global talent acquisition quintiles service commercial services white paper white paper supporting the patient journey quintiles service commercial services innovation is essential to driving success in healthcare seeing your challenges clearly and understanding your clinical and commercial opportunities early is key to maximizing performance we can offer the necessary data commercial experience scientific depth and operational expertise to help you advance clinical outcomes and commercial performance – so you can focus on bringing your innovations to patients market accessproduct launchadvisory servicespatient education fact sheet quintilesims commercial outsourcing solutions brochure creating better global market access strategies white paper value to outcomes  v  quintiles solutions realworld insights quintiles solutions realworld insights healthcare stakeholders are increasingly seeking realworld evidence to support regulatory reimbursement and prescribing decisions but different stakeholders demand different types and rigors of evidence generate realworld insights using anonymized patientlevel data and comprehensive evidence development approaches to build the evidence you need for regulators payers providers and patients realworld  late phase strategyrealworld data  analyticsobservational research  registries brochure realworld  late phase the right approach for the right question fact sheet quintiles scientific affairs the right choice for realworld scientific expertise white paper value to outcomes  v  quintiles insights how advances in riskbased monitoring will enable a more proactive approach to identify and mitigate potential risks rajneesh patil mba pm senior director riskbased monitoring and analytics blog post blog post predictive analytics and the future of rbm quintiles solutions technology quintiles solutions technology connect insights with superior delivery for better outcomes our awardwinning technology solutions help optimize processes and enhance our biopharma expertise to make faster more informed decisions that minimize risk and maximize value for your business comprehensive technology solutionsclinical trial planning  designmodelbased drug development white paper can better planning save biopharma clinical trial planning  design video asset quintiles datadriven trial execution brochure empowering healthcare research with real world data quintiles awards being named to the fortune magazine list of the “world’s most admired companies®” is evidence that both our peers and our clients understand the long term strategy and value our organization provides to our clients this honor is built upon the dedication and focus of our more than  employees around the world to create solutions that help our clients drive healthcare forward ari bousbib quintilesims chairman and ceo ims health and quintiles to merge  quintilesims menu about us investor relations services therapeutics insights careers events  webinars investigators global markets contact us our focus our history awards  recognition sustainability ethics  compliance news media contacts modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines about us our focus our history awards  recognition sustainability ethics  compliance news media contacts investor relations services advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology therapeutics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines insights careers events  webinars investigators global markets contact us home quintiles news ims health and quintiles to merge press release may   ims health and quintiles to merge quintiles ims to become industryleading information and technologyenabled healthcare service provider allstock transaction with combined  revenue of  billion and combined equity market capitalization of  billion broad range of healthcare information technology and services solutions to drive efficiencies and insights across the entire life sciences product lifecycle from rd through commercial execution to realworld patient outcomes capabilities to address missioncritical healthcare operations with a market opportunity of more than  billion quintiles ims will accelerate patient access to innovative medicines by increasing the productivity of the  billion spent on drug development demonstrate the value and effectiveness of medicines as part of the  billion opportunity for realworld evidence rwe services and connected healthcare drive a greater return on investment from the  billion that life sciences companies spend annually on commercial and field operations create one of the world’s largest portfolios of healthcare information deep therapeutic domain regulatory and commercial analytic expertise as well as proprietary technology applications supported by more than  employees operating in  countries assemble an experienced management team with proven track record of operational excellence offer compelling commercial operational and financial synergies combined annual revenue growth rate anticipated to increase by  to  basis points by the end of year three annual runrate cost savings expected to be  million by the end of year three optimized tax and capital structure accretive to adjusted diluted eps in  danbury ct and research triangle park nc may   – ims health holdings inc nyseims and quintiles transnational holdings inc nyseq announced today that their respective boards of directors approved a definitive merger agreement pursuant to which the companies will be combined in an allstock merger of equals transaction the merged company will be named quintiles ims holdings inc based on the closing of ims health and quintiles common stock prices on may   the equity market capitalization of the joined companies is more than  billion and the enterprise value is more than  billion the  pro forma reported revenue for quintiles ims was  billion adjusted ebitda was  billion and adjusted unlevered free cash flow was  billion please see attached appendix for reconciliation of nongaap measures under the terms of the merger agreement ims health shareholders will receive a fixed exchange ratio of  shares of quintiles common stock for each share of ims health common stock upon completion of the merger ims health shareholders will own approximately  percent of the shares of the combined company on a fully diluted basis and quintiles shareholders will own approximately  percent of the combined company on a fully diluted basis quintiles chief executive officer tom pike said “this combination addresses lifescience companies’ most pressing needs to transform the clinical development of innovative medicines demonstrate the value of these medicines in the real world and drive commercial success we are bringing together two bestinclass leaders i’m confident that together we will make our clients even more successful” ari bousbib chairman and chief executive officer of ims health stated “together our solutions will enable differentiation in the cro market advance realworld evidence capabilities and deliver comprehensive commercial solutions for our clients this powerful combination brings together leading technology and analytics with deep scientific expertise delivered on a global scale by our  immensely talented professionals in more than  markets our combined business will accelerate growth yield greater operating efficiencies and provide more flexibility for future expansion” strategic rationale improve clinical trial design recruitment and execution in the  billion biopharma product development market by combining ims health’s rich global information solutions with quintiles’ industryleading product development skills  create a distinctive global realworld evidence solutions platform by combining a leading portfolio of anonymous patient records technologyenabled data collection and observational research experts to address critical healthcare issues of cost value and patient outcomes  further differentiate commercial analytics and outsourcing services to support the efficiency of life sciences’ commercial organizations  financial rationale  accelerate revenue growth adding an anticipated    basis points to the combined annual growth rate by the end of year three  expect to achieve annual runrate cost savings of m by the end of year three  accretive to adjusted diluted eps in   maintain financial flexibility with combined gross and net leverage as of december   of  times and  times adjusted ebitda respectively  optimize utilization of both companies’ tax assets management governance and headquarters the combined company expects to maintain dual headquarters in danbury ct and research triangle park nc ari bousbib chairman and chief executive officer of ims health will become chairman and chief executive officer of the merged organization tom pike chief executive officer of quintiles will become vice chairman the company’s board of directors will be comprised of six directors appointed by the quintiles board of directors and six directors appointed by the ims health board of directors the lead director will be dennis gillings cbe phd approvals and time to close the transaction is subject to customary closing conditions including regulatory approvals and approval by both ims health and quintiles shareholders and is expected to close in the second half of  shareholders of ims health owning approximately  percent of the common stock of ims health and shareholders of quintiles owning approximately  percent of the common stock of quintiles have entered into agreements to vote the portion of their shares over which they have voting power to vote in favor of the transaction the companies intend to refinance certain debt in connection with the merger committed financing has been obtained   advisors ims health’s legal advisor is weil gotshal  manges llp and its financial advisor is goldman sachs  co in addition morris nichols arsht  tunnell llp served as legal advisor to the independent committee of the ims health board of directors quintiles’ legal advisors are bryan cave llp and smith anderson blount dorsett mitchell  jernigan llp and its financial advisor is barclays simpson thacher  bartlett llp served as legal advisor to quintiles’ independent directors joint conference call and webcast details quintiles’ and ims health’s management teams will host a conference call and webcast to discuss the merger of equals at  am eastern time on may   interested parties are invited to listen to the live event and view the presentation slides via webcast on ims health’s investor relations website at httpirimshealthcom or on quintiles’ investor relations website at wwwquintilescominvestors participants can access the handouts before the teleconference begins the discussion also will be available by dialing  in the us and canada or  for international callers a replay of the webcast will be available approximately two hours after the conclusion of the live event on may   to access the webcast recording visit httpirimshealthcom or wwwquintilescominvestors about ims health ims health nyseims is a leading global information and technology services company providing clients in the healthcare industry with endtoend solutions to measure and improve their performance our  services experts connect configurable saas applications to  petabytes of complex healthcare data in the ims one™ cloud platform delivering unique insights into diseases treatments costs and outcomes the company’s  employees blend global consistency and local market knowledge across  countries to help clients run their operations more efficiently customers include pharmaceutical consumer health and medical device manufacturers and distributors providers payers government agencies policymakers researchers and the financial community as a global leader in protecting individual patient privacy ims health uses anonymous healthcare data to deliver critical realworld disease and treatment insights these insights help biotech and pharmaceutical companies medical researchers government agencies payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes additional information is available at wwwimshealthcom about quintiles quintiles nyseq helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific therapeutic and analytics expertise with superior delivery for better outcomes from advisory through operations quintiles is the world’s largest provider of product development and integrated healthcare services including commercial and observational solutions conducting operations in approximately  countries quintiles is a member of the fortune  and has been named to fortune’s list of the “world’s most admired companies” to learn more visit wwwquintilescom cautionary statements   regarding forward looking statements this communication contains “forwardlooking statements” within the meaning of the federal securities laws including section a of the securities act of  as amended and section e of the securities exchange act of  as amended in this context forwardlooking statements often address expected future business and financial performance and financial condition and often contain words such as “expect” “anticipate” “intend” “plan” “believe” “seek” “see” “will” “would” “target” similar expressions and variations or negatives of these words forwardlooking statements by their nature address matters that are to different degrees uncertain such as statements about the potential timing or consummation of the proposed transaction or the anticipated benefits thereof including without limitation future financial and operating results ims health and quintiles caution readers that these and other forwardlooking statements are not guarantees of future results and are subject to risks uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forwardlooking statements important risk factors that may cause such a difference include but are not limited to risks and uncertainties related to i the ability to obtain shareholder and regulatory approvals or the possibility that they may delay the transaction or that such regulatory approval may result in the imposition of conditions that could cause the parties to abandon the transaction ii the risk that a condition to closing of the merger may not be satisfied iii the ability of ims health and quintiles to integrate their businesses successfully and to achieve anticipated cost savings and other synergies iv the possibility that other anticipated benefits of the proposed transaction will not be realized including without limitation anticipated revenues expenses earnings and other financial results and growth and expansion of the new combined company’s operations and the anticipated tax treatment v potential litigation relating to the proposed transaction that could be instituted against ims health quintiles or their respective directors vi possible disruptions from the proposed transaction that could harm ims health’s or quintiles’ business including current plans and operations vii the ability of ims health or quintiles to retain attract and hire key personnel viii potential adverse reactions or changes to relationships with clients employees suppliers or other parties resulting from the announcement or completion of the merger ix potential business uncertainty including changes to existing business relationships during the pendency of the merger that could affect ims health’s andor quintiles’ financial performance x certain restrictions during the pendency of the merger that may impact ims health’s or quintiles’ ability to pursue certain business opportunities or strategic transactions xi continued availability of capital and financing and rating agency actions xii legislative regulatory and economic developments and xiii unpredictability and severity of catastrophic events including but not limited to acts of terrorism or outbreak of war or hostilities as well as management’s response to any of the aforementioned factors these risks as well as other risks associated with the proposed transaction will be more fully discussed in the joint proxy statementprospectus that will be included in the registration statement on form s that will be filed with the sec in connection with the proposed transaction while the list of factors presented here is and the list of factors to be presented in the registration statement on form s are considered representative no such list should be considered to be a complete statement of all potential risks and uncertainties unlisted factors may present significant additional obstacles to the realization of forward looking statements consequences of material differences in results as compared with those anticipated in the forwardlooking statements could include among other things business disruption operational problems financial loss legal liability to third parties and similar risks any of which could have a material adverse effect on ims health’s or quintiles’ consolidated financial condition results of operations credit rating or liquidity neither ims health nor quintiles assumes any obligation to provide revisions or updates to any forward looking statements whether as a result of new information future developments or otherwise should circumstances change except as otherwise required by securities and other applicable laws contacts tor constantino  ims health media relations   tconstantinousimshealthcom tom kinsley  ims health investor relations   tkinsleyimshealthcom phil bridges quintiles media relations   philbridgesquintilescom todd kasper  quintiles investor relations  investorrelationsquintilescom cro clinical trial services pharmaceutical consulting  quintilesims menu about us investor relations services therapeutics insights careers events  webinars investigators global markets contact us our focus our history awards  recognition sustainability ethics  compliance news media contacts modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines about us our focus our history awards  recognition sustainability ethics  compliance news media contacts investor relations services advisory services biopharmaceutical rd biopharmaceuticals sales  marketing biosimilars biostatistics brand  scientific communications cardiac safety ecg monitoring clinical trial planning  design contract sales data management emerging biopharma enriched studies functional service provider generic clinical development late phase clinical trials market access market entryexit marketed product maintenance medical device  diagnostics modelbased drug development observational research  registries patient engagement services patient recruitment payers  providers phase iiia and early clinical trials phase iiiii clinical trials phase iiibiv clinical trials precision medicine product launch project management realworld  late phase strategy realworld data  analytics regulatory affairs riskbased monitoring safety  pharmacovigilance site startup specialty clinical associations  patient organization technology therapeutics acute care  pain allergy  respiratory cardiovascular central nervous system diabetes immunology infectious diseases internal medicine oncology pediatrics public health interest rare disease vaccines insights careers events  webinars investigators global markets contact us solutions for you to drive healthcare forward quintiles and imshealth have merged to form quintilesims find out more who we are about us news featured services precision medicine riskbased monitoring oncology realworld  late phase strategy market access advisory services how we think blog authors peerreviewed publications library events  webinars tradeshows webinars quintiles service emerging biopharma quintiles service emerging biopharma specific needs arise from operating and leading a small organization–getting to your next milestone ensuring funding delivering studies while managing resource constraints and launch planning just to name a few the future of your programs your company and the practitioners and patients you are aiming to help are all at stake by offering personalized attention and global therapeutic expertise quintilesims can help you confidently create and deliver the right evidence generation plan and optimize your asset value emerging biopharmaclinical developmentplanning and designmarket access and commercialization fact sheet solutions for emerging biopharma presentation strategic considerations for clinical development programs in emerging biopharma companies presentation optimizing realworld evidence programs to generate value your request for information or proposal area of interest access to patients clinical services clinical trials commercial services consulting services early clinical development late phase services quintiles infosario regulatory services   quintiles solutions clinical development quintiles solutions clinical development transform clinical development by connecting healthcare data new technologies advanced methodologies and scientific expertise together these resources increase your understanding of how patients are treated and which sites have the potential targeted population they also help provide understanding around what clinical outcomes lead to commercial success and offer realworld information to help you confidently value your advancements riskbased monitoringrare disease oncologyinsights on clinical developmentprecision enrollment for sites white paper riskbased monitoring improves site performance and investigator satisfaction infographic tailored solution for rare disease studies white paper transforming patient recruitment through patient and site engagement quintiles careers join us and get the satisfaction of doing great work that matters we are looking for talented professionals who share our values and passion to create a healthier world we are the industry leader and can provide you with the tools and resources needed to succeed and offer great career path opportunities erica briody vice president global talent acquisition quintiles service commercial services white paper white paper supporting the patient journey quintiles service commercial services innovation is essential to driving success in healthcare seeing your challenges clearly and understanding your clinical and commercial opportunities early is key to maximizing performance we can offer the necessary data commercial experience scientific depth and operational expertise to help you advance clinical outcomes and commercial performance – so you can focus on bringing your innovations to patients market accessproduct launchadvisory servicespatient education fact sheet quintilesims commercial outsourcing solutions brochure creating better global market access strategies white paper value to outcomes  v  quintiles solutions realworld insights quintiles solutions realworld insights healthcare stakeholders are increasingly seeking realworld evidence to support regulatory reimbursement and prescribing decisions but different stakeholders demand different types and rigors of evidence generate realworld insights using anonymized patientlevel data and comprehensive evidence development approaches to build the evidence you need for regulators payers providers and patients realworld  late phase strategyrealworld data  analyticsobservational research  registries brochure realworld  late phase the right approach for the right question fact sheet quintiles scientific affairs the right choice for realworld scientific expertise white paper value to outcomes  v  quintiles insights how advances in riskbased monitoring will enable a more proactive approach to identify and mitigate potential risks rajneesh patil mba pm senior director riskbased monitoring and analytics blog post blog post predictive analytics and the future of rbm quintiles solutions technology quintiles solutions technology connect insights with superior delivery for better outcomes our awardwinning technology solutions help optimize processes and enhance our biopharma expertise to make faster more informed decisions that minimize risk and maximize value for your business comprehensive technology solutionsclinical trial planning  designmodelbased drug development white paper can better planning save biopharma clinical trial planning  design video asset quintiles datadriven trial execution brochure empowering healthcare research with real world data quintiles awards being named to the fortune magazine list of the “world’s most admired companies®” is evidence that both our peers and our clients understand the long term strategy and value our organization provides to our clients this honor is built upon the dedication and focus of our more than  employees around the world to create solutions that help our clients drive healthcare forward ari bousbib quintilesims chairman and ceo smith asset management group lp has increased quintiles ims holdings q stake last week cvs health cvs analysts  bibey post trending stock news penny stock news market news stock news smith asset management group lp has increased quintiles ims holdings q stake last week cvs health cvs analysts july    by henry gaston smith asset management group lp increased quintiles ims holdings inc q stake by  reported in q sec filing smith asset management group lp acquired  shares as quintiles ims holdings inc q’s stock rose  the smith asset management group lp holds  shares with  million value up from  last quarter quintiles ims holdings inc now has  billion valuation the stock increased  or  during the last trading session reaching  about shares traded quintiles ims holdings inc nyseq has risen  since july   and is uptrending it has outperformed by  the sp among  analysts covering cvs health nysecvs  have buy rating  sell and  hold therefore  are positive cvs health had  analyst reports since july   according to sratingsintel the firm has “buy” rating by mizuho given on wednesday november  oppenheimer maintained it with “outperform” rating and  target in thursday december  report argus research maintained cvs health corp nysecvs on monday august  with “buy” rating evercore reinitiated the shares of cvs in report on wednesday august  with “buy” rating the firm has “neutral” rating by goldman sachs given on thursday december  the firm has “neutral” rating by atlantic securities given on monday february  the firm has “outperform” rating given on friday january  by robert w baird jp morgan maintained cvs health corp nysecvs rating on monday november  jp morgan has “overweight” rating and  target the firm earned “neutral” rating on thursday february  by robert w baird the firm has “buy” rating given on thursday october  by ubs see cvs health corp nysecvs latest ratings  broker credit suisse rating buy new target   broker leerink swann rating buy new target   broker cowen  co rating buy maintain broker jefferies rating hold new target  maintain broker needham rating hold initiates coverage on broker tigress financial rating buy initiate broker atlantic securities old rating overweight new rating neutral downgrade broker robert w baird old rating outperform new rating neutral old target  new target  downgrade among  analysts covering quintiles transnational nyseq  have buy rating  sell and  hold therefore  are positive quintiles transnational had  analyst reports since july   according to sratingsintel the stock of quintiles ims holdings inc nyseq has “neutral” rating given on tuesday december  by mizuho the rating was upgraded by robert w baird on friday july  to “neutral” the stock of quintiles ims holdings inc nyseq has “outperform” rating given on friday february  by wells fargo as per friday december  the company rating was downgraded by bank of america on friday february  the stock rating was upgraded by deutsche bank to “buy” jefferies downgraded the stock to “hold” rating in wednesday october  report the rating was maintained by argus research on thursday july  with “buy” the firm has “buy” rating by zacks given on tuesday august  as per thursday december  the company rating was downgraded by raymond james the rating was downgraded by william blair to “market perform” on thursday december  investors sentiment increased to  in  q its up  from  in q it is positive as  investors sold q shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  more from  million shares in q were reported tiaa cref management ltd liability corporation owns m shares cryder capital limited liability partnership a united kingdombased fund reported  shares van eck associate corporation stated it has  shares or  of all its holdings commonwealth equity accumulated  shares profund advsr ltd liability corp reported  shares dekabank deutsche girozentrale holds  or  shares in its portfolio blackrock lc reported  shares chicago equity prns ltd liability corporation accumulated  shares creative planning accumulated  or  shares credit suisse ag invested in  or  shares globeflex capital lp stated it has  of its portfolio in quintiles ims holdings inc nyseq moreover glenmede trust co na has  invested in quintiles ims holdings inc nyseq steadfast capital lp owns m shares neuberger berman group ltd com accumulated  shares teachers retirement of the state of kentucky holds  shares smith asset management group lp decreased arista networks inc nyseanet stake by  shares to  valued at  million in q it also reduced cintas corp nasdaqctas stake by  shares and now owns  shares cadence design systems inc nasdaqcdns was reduced too investors sentiment decreased to  in  q its down  from  in q it turned negative as  investors sold cvs health corp shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  less from  million shares in q were reported vantage ltd limited liability company reported  in cvs health corp nysecvs tiedemann wealth mgmt limited liability co holds  or  shares in its portfolio advsr ltd limited liability co reported  stake daiwa securities owns  shares or  of their us portfolio vestor capital ltd co holds  or  shares commonwealth financial bank of australia holds  shares or  of its portfolio stelac advisory services lc invested  of its portfolio in cvs health corp nysecvs highland capital ltd reported  shares ally invested in  shares eads heald inv counsel holds  in cvs health corp nysecvs or  shares m were reported by retirement systems of alabama texas yale corporation has invested  in cvs health corp nysecvs midwest mngmt ltd llc reported  shares or  of all its holdings iowa commercial bank accumulated  or  shares first comml bank of mount dora inv owns  invested in cvs health corp nysecvs for  shares cvs health corporation together with its subsidiaries is an integrated pharmacy healthcare company the company has market cap of  billion the firm provides pharmacy care for the senior community through omnicare inc and omnicare’s longterm care ltc operations which include distribution of pharmaceuticals related pharmacy consulting and other ancillary services to chronic care facilities and other care settings it has a  pe ratio it operates through three divisions pharmacy services retailltc and corporate about  shares traded cvs health corp nysecvs has declined  since july   and is downtrending it has underperformed by  the sp by henry gaston echostar corporationreceive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter free newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts hicrush partners lp hclp is at  formed wedge kroger co kr’s sentiment is  internap inap analysts see  eps marathon oil mro sentiment is  amica mutual insurance company has raised its t rowe price group trow holding last week dicerna pharmaceuticals drna coverage malaga cove capital increased jacobs engr group del jec position kingdon capital management trimmed by  million its dynavax technologies call dvax holding lee danner  bass trimmed mondelez int’l mdlz holding smc corporation smecf shorts down by  cathay general bancorp caty is at  formed wedge spartannash co sptn had  bulls lee danner  bass boosted level  commun lvlt holding by  aetna aet sentiment is  analysts see  eps for haynes international inc hayn slm slm shorts increased by  tiaa cref trust company fsb has increased air products  chemicals apd stake by  discover financial services dfs’s sentiment is  deutsche global high income fund lbf is at  formed wedge allstate all sentiment is   copyright  bibey post inc  bibeypostcom       about  our team  contact creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی  語   한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info quintilesims  wikipedia quintilesims from wikipedia the free encyclopedia   redirected from quintiles jump to navigation search for quintiles the statistical distribution grouping into fifths see quantile quintiles ims holdings inc type public traded as nyse q russell  component industry contract research organization pharmaceutical service consulting founded  headquarters durham north carolina usa key people dennis gillings founder ari bousbib chairman and ceo products support services for pharmaceutical biotech and medical companies and individuals revenue us  billion  number of employees    website httpwwwquintilesimscom quintiles ims holdings inc branded as quintilesims is an american multinational company serving the combined industries of health information technologies and clinical research it is a fortune  company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than  employees conducting business in approximately  countries quintilesims is the world’s largest contract research organization as ranked by reported service revenues and is focused primarily on phase iiiv clinical trials and associated laboratory and analytical services historyedit in  dennis gillings founded and incorporated quintiles transnational in north carolina quintiles transnational established quintiles pacific inc and quintiles ireland ltd in  and in  quintiles gmbh was established in germany and quintiles laboratories ltd was established in atlanta georgia in september  quintiles purchased innovex ltd of britain for  million in stock quintiles went public in  and completed a successful secondary stock offering over  concluding on october  quintiles underwent a  billion merger with ims health becoming quintilesims referencesedit  fortune   a b c smith rick quintiles ims health complete b merger no word on any job cuts wral techwire capitol broadcasting corporation inc retrieved    inside quintiles the worlds largest cro outsourcingpharmacom   matthew herper november   money math and medicine forbes magazine retrieved july     quintiles pacific inc private company information  businessweek   quintiles laboratories limited private company information  businessweek   derdak t atkins w  quintiles transnational corp encyclopediacom cs maint uses authors parameter link  olivia oran  may  quintiles ipo raises morethanplanned  million as stocks rally reuters   henderson jennifer  october  quintiles ims health complete merger triangle business journal american city business journals retrieved  october   external linksedit quintilesims website retrieved from httpsenwikipediaorgwindexphptitlequintilesimsoldid categories companies listed on the new york stock exchangecompanies based in reading berkshirecompanies based in durham north carolinacompanies based in north carolina by citycontract research organizationscompanies established in life sciences industry establishments in north carolina initial public offeringscompanies formed by mergerhidden categories cs maint uses authors parameter navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages italianoрусский edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view quintilesims  wikipedia quintilesims from wikipedia the free encyclopedia   redirected from quintiles jump to navigation search for quintiles the statistical distribution grouping into fifths see quantile quintiles ims holdings inc type public traded as nyse q russell  component industry contract research organization pharmaceutical service consulting founded  headquarters durham north carolina usa key people dennis gillings founder ari bousbib chairman and ceo products support services for pharmaceutical biotech and medical companies and individuals revenue us  billion  number of employees    website httpwwwquintilesimscom quintiles ims holdings inc branded as quintilesims is an american multinational company serving the combined industries of health information technologies and clinical research it is a fortune  company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than  employees conducting business in approximately  countries quintilesims is the world’s largest contract research organization as ranked by reported service revenues and is focused primarily on phase iiiv clinical trials and associated laboratory and analytical services historyedit in  dennis gillings founded and incorporated quintiles transnational in north carolina quintiles transnational established quintiles pacific inc and quintiles ireland ltd in  and in  quintiles gmbh was established in germany and quintiles laboratories ltd was established in atlanta georgia in september  quintiles purchased innovex ltd of britain for  million in stock quintiles went public in  and completed a successful secondary stock offering over  concluding on october  quintiles underwent a  billion merger with ims health becoming quintilesims referencesedit  fortune   a b c smith rick quintiles ims health complete b merger no word on any job cuts wral techwire capitol broadcasting corporation inc retrieved    inside quintiles the worlds largest cro outsourcingpharmacom   matthew herper november   money math and medicine forbes magazine retrieved july     quintiles pacific inc private company information  businessweek   quintiles laboratories limited private company information  businessweek   derdak t atkins w  quintiles transnational corp encyclopediacom cs maint uses authors parameter link  olivia oran  may  quintiles ipo raises morethanplanned  million as stocks rally reuters   henderson jennifer  october  quintiles ims health complete merger triangle business journal american city business journals retrieved  october   external linksedit quintilesims website retrieved from httpsenwikipediaorgwindexphptitlequintilesimsoldid categories companies listed on the new york stock exchangecompanies based in reading berkshirecompanies based in durham north carolinacompanies based in north carolina by citycontract research organizationscompanies established in life sciences industry establishments in north carolina initial public offeringscompanies formed by mergerhidden categories cs maint uses authors parameter navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages italianoрусский edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view our difference  quintilesims transform clinical development create commercial value lead with realworld insights innovate with technology our difference our difference we were excited to think about what if now we want to bring you what’s next each of our companies started off small two people a vision and determination to change the way healthcare worked at ims it was creating information about healthcare activity that never existed before for quintiles it was introducing data science to drug developmentwe continue to have bold ambitions quintilesims is proud to bring you our combined data expertise technology and operational capabilities but what is really new is that we are connecting these in ways that haven’t been seen before and that will empower us to provide new solutions to help you move healthcare forward our technologiestechnology solutions to power your competitive differentiation and accelerate your business model transformationproprietary it platforms and technologies supporting thousands of commercial engagements clinical trials and realworld studies conducted globally every yearawardwinning safety platform provides  ontime compliance to regulatory authorities our clinical and commercial operationswe integrate execution capabilities seamlessly across disciplines to support our solutions as well as your outsourcing needsthousands of proprietary methodologies including patented systems for analytics data encryption and forecasting our datathe world’s largest and most diverse set of healthcare information including privacy protected anonymized patient level data to provide granularityour peoplean uncommon blend of clinical commercial data and technology experts all working together to create solutions that cut across disciplines featured quintilesims institute report global oncology trends   advances complexity and cost over the past decade there has been a paradigm shift in the treatment of cancer driven by advances in personalized medicine and immunooncology in this report we share our perspective on some of the trends observed in  including impact on cancer outcomes the redefinition of many cancers availability and costs of oncology therapeutics and complexity in cancer treatments read report we cannot just claim to bring clinical commercial and realworld insights together because we put them into one company  we have to make it happen  and it is by connecting our capabilities in new ways throughout the product lifecycle that we doimproving clinical study efficiency and execution by infusing data and science seamlessly and early bringing together prospective and retrospective research to develop a richer understanding of realworld practice and outcomes delivering innovative consulting services through a lens of scientific expertise and practical experience developing technology solutions based on the healthcare data they use and the healthcare applications they supportproviding endtoend solutions by integrating clinical and commercial operations inhouse × want to contact us about a solution thank you for contacting quintilesims during this exciting time we will be in contact with you as soon as possible complete the form below and a member of our team will be in contact regarding your business need please fill in all required fields my inquiry is regarding request for proposal request for information tell us more about you industry associations animal health association biotech biotech emerging competitor consumer health devices diagnostics financial community foundation ghcc government hospital information  service providers insurer intermediaries  distributors investment bank investor law firm managed care media medical devices  diagnostics nonprofit other partner payers pharma private equity providers suppliers to pharma third partysupplier university primary responsibility administration  insurance biostatistics clinical and rd clinical research corp strategy  business development data management distribution executive management field sales finance  market research forecasting functional service provider fsp general management health economics health economics  outcomes research health outcomes human resources information management information technology intellectual property laboratory legal managed markets managemet consultant market access market research marketing marketing brand  product marketing communications  pr marketing database marketing digital marketing operations medical affairs medical devices medical institutions medical writing nonregistration studies other outsourcing packaging patient centric services pharmacogenomics pharmacovigilance pricing and market access pricing and reimbursement procurement public affairs regulatory sales sales  marketing sales management sales operations sales support scientific service strategy supplies temas training tell us where you are tell us what you are interested in select the therapy area you need antibioticsantifungals acute care allergyimmunology autoimmune biologics cardiovascular central nervous system dermatology diabetes endocrinology erytropoetine epo female health gastroenterology gastrointestinal growth hormones hematology hepatitus c hepatology hivantivirals immunomodulators infectious disease medical genetics metabolics nephrology neurology oncology ophthalmology orthopaedics other pain psychiatry respiratory rheumatoid arthritis rheumatology transplantation urology vaccines womens healthsexual health please check recaptcha   by submitting this form i agree to receive email communications from quintilesims group of companies × want to contact us about a solution thank you for contacting quintilesims during this exciting time we will be in contact with you as soon as possible complete the form below and a member of our team will be in contact regarding your business need please fill in all required fields my inquiry is regarding request for proposal request for information tell us more about you industry associations animal health association biotech biotech emerging competitor consumer health devices diagnostics financial community foundation ghcc government hospital information  service providers insurer intermediaries  distributors investment bank investor law firm managed care media medical devices  diagnostics nonprofit other partner payers pharma private equity providers suppliers to pharma third partysupplier university venture capital primary responsibility administration  insurance biostatistics clinical and rd clinical research corp strategy  business development data management distribution executive management field sales finance  market research forecasting functional service provider fsp general management health economics health economics  outcomes research health outcomes human resources information management information technology intellectual property laboratory legal managed markets managemet consultant market access market research marketing marketing brand  product marketing communications  pr marketing database marketing digital marketing operations medical affairs medical devices medical institutions medical writing nonregistration studies other outsourcing packaging patient centric services pharmacogenomics pharmacovigilance pricing and market access pricing and reimbursement procurement public affairs regulatory sales sales  marketing sales management sales operations sales support scientific service strategy supplies temas training tell us where you are tell us what you are interested in select the therapy area you need antibioticsantifungals acute care allergyimmunology autoimmune biologics cardiovascular central nervous system dermatology diabetes endocrinology erytropoetine epo female health gastroenterology gastrointestinal growth hormones hematology hepatitus c hepatology hivantivirals immunomodulators infectious disease medical genetics metabolics nephrology neurology oncology ophthalmology orthopaedics other pain psychiatry respiratory rheumatoid arthritis rheumatology transplantation urology vaccines womens healthsexual health please check recaptcha   by submitting this form i agree to receive email communications from quintilesims group of companies transform clinical development create commercial value lead with realworld insights innovate with technology our difference about us investors careers contact us quintilesims institute privacy statement terms of use suppliers imshealthcom quintilescom copyright   quintilesims all rights reserved home  quintilesims transform clinical development create commercial value lead with realworld insights innovate with technology our difference our difference quintilesims  imagine our combined data expertise technology and capabilities connecting in ways that haven’t been seen before learn more transform clinical development pave a more precise and predictable path to product approval and beyond learn more create commercial value rethink commercialization with an unexpected mix of expertise and operational capabilities learn more realworld insights apply realworld data across functions and geographies to meet multistakeholder demands learn more innovate with technology orchestrate your business success with cloudbased technology solutions learn more previous next welcome to quintilesims a new company built from a foundation of deep experience and capabilities we’re designing our approach to help our clients move healthcare forward new ways to improve clinical trials more robust evidence to support treatments a clearer picture of the patient journey insights that actually lead to better commercial performance you set your goals quintilesims is here to help you get there with confidence solutions transform clinical development new ways to drive clinical trials forward create commercial value rethink commercialization with an unexpected mix of expertise and operational capabilities realworld insights global realworld data transforms healthcare by improving your understanding of patients treatments outcomes and costs innovate with technology orchestrate success with cloudbased technology solutions our difference quintilesims  imagine our combined data expertise technology and capabilities connecting in ways that haven’t been seen before learn more about us quintilesims delivers integrated information and technology solutions to drive healthcare forward learn more featured quintilesims institute report global oncology trends   advances complexity and cost over the past decade there has been a paradigm shift in the treatment of cancer driven by advances in personalized medicine and immunooncology in this report we share our perspective on some of the trends observed in  including impact on cancer outcomes the redefinition of many cancers availability and costs of oncology therapeutics and complexity in cancer treatments read report press releases colleen goggins joins quintilesims board of directors quintilesims to announce secondquarter  results on august   quintilesims introduces orchestrated customer engagement oce tweets byparameterstwitteraccount transform clinical development create commercial value lead with realworld insights innovate with technology our difference about us investors careers contact us quintilesims institute privacy statement terms of use suppliers imshealthcom quintilescom copyright   quintilesims all rights reserved quintiles ims holdings inc  quintilesims merger creates a leading global integrated information and technologyenabled healthcare service provider skip to main content no logo about us investors careers contact us browse solutions transform clinical development create commercial value lead with realworld insights innovate with technology our difference about us investors careers contact us press releases press release details view all press releases oct   quintilesims merger creates a leading global integrated information and technologyenabled healthcare service provider download this press release pdf format opens in new window  danbury conn  research triangle park nc october   – quintiles ims holdings inc nyseq today announced that it has successfully completed its merger of equals transaction between ims health holdings inc nyseims and quintiles transnational holdings inc the merger of ims health a leading global information and technology services company and quintiles the world’s largest provider of product development and integrated healthcare services creates a leading information and techenabled healthcare service provider with global scale and reach and a full suite of endtoend clinical and commercial offerings merger close details today ims health merged into quintiles with quintiles as the surviving company renamed quintiles ims holdings inc and known as quintilesims shares of ims health were halted from trading today on the nyse and will no longer be traded under the terms of the merger agreement at the effective time of the merger each share of ims health was automatically converted into  of a share of quintiles stock about quintilesims quintilesims nyseq is a leading integrated information and technologyenabled healthcare service provider worldwide dedicated to helping its clients improve their clinical scientific and commercial results formed through the merger of quintiles and ims health quintilesims’s approximately  employees conduct operations in more than  countries companies seeking to improve realworld patient outcomes and enhanced clinical trial outsourcing through treatment innovations care provision and access can leverage quintilesims’s broad range of healthcare information technology and service solutions to drive new insights and approaches quintilesims provides solutions that span clinical to commercial bringing clients a unique opportunity to realize the full potential of innovations and advance healthcare outcomes as a global leader in protecting individual patient privacy quintilesims uses healthcare data to deliver critical realworld disease and treatment insights through a wide variety of privacyenhancing technologies and safeguards quintilesims protects individual privacy while managing information to drive healthcare forward these insights and execution capabilities help biotech medical device and pharmaceutical companies medical researchers government agencies payers and other healthcare stakeholders in the development and approval of new therapies identify unmet treatment needs and understand the safety effectiveness and value of pharmaceutical products in improving overall health outcomes to learn more visit wwwquintilesimscom view all press releases investor toolkit print this page email alerts email this page ir contacts rss feeds sign up for our investor alerts email address  mailing lists  press releases sec filings presentation events eod stock quote annual report   enter the code shown above  investor contact  wooster heights road danbury connecticut  usa tel     emperor boulevard durham north carolina  usa tel    email irquintilesimscom transform clinical development create commercial value lead with realworld insights innovate with technology our difference transform clinical development create commercial value lead with realworld insights innovate with technology our difference about us investors careers contact us privacy statement terms of use suppliers imshealthcom quintilescom twitter linkedin copyright  quintilesims all rights reserved twitter linkedin powered by q inc  opens in new window quintiles ims holdings q holds secondary offering revisedhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp futures dow futures nasdaq futures quintiles ims holdings q holds secondary offering revisedzacks equity researchzacksjune  reblogsharetweetshareleading provider of product development and integrated healthcare services quintiles ims holdings inc q held a secondary offering of m shares of which they repurchased m worthstock performancein the last three months quintiles’ shares have increased roughly  against the zacks categorized medical services’ subindustry’s loss of  the current level is higher than the sp ’s return of  over the same time frame finally a longterm expected earnings growth rate of  instills confidence in investorsthe estimate revision for the stock has been unfavorable the current quarter has seen seven estimates move south over the last month compared with one movement in the opposite direction as a result earnings estimates for the current quarter have declined  cents to  over the same period quintiles’ carries a zacks rank  hold the transaction is expected to close on may   subject to customary closing conditions the company expects to fund the repurchase with cash on hand and borrowings from its revolving credit facility as of mar   the company had  million of cash and cash equivalents in its bookslooking forward we believe inorganic expansion has acted as a major catalyst for the company the strategic alliance with davita clinical research a wholly owned subsidiary of davita healthcare is a notable development from this transaction quintiles is expected to gain nephrology expertise and enhance its global delivery capabilities which will fortify its position in the field of clinical research the company has  years of experience in the field of clinical trial research especially in therapeuticsthe launch of continuous glucose monitoring service is a major growth driver for quintiles notably the solution offers innovative and wearable technology for diabetesfocused clinical trials which is highly exclusive in the market in this regard a report by markets and markets forecasts that the global market for glucose dextrose and maltodextrin is projected to reach a worth of  billion by  at a cagr of key picksbetterranked stocks in the broader medical sector include luminex corporation lmnx edwards lifesciences corp ew and inogen inc ingn inogen and luminex sport a zacks rank  strong buy while edwards lifesciences carries a zacks rank  buy you can see the complete list of today’s zacks  strong buy rank stocks hereinogen projects a longterm adjusted earnings growth of almost  the stock returned  over the last one yearluminex has an expected longterm adjusted earnings growth of almost  the stock added roughly  over the last three monthsedwards lifesciences has a longterm expected earnings growth rate of  the stock has a solid oneyear return of roughly more stock news  companies verge on applelike run did you miss apples x stock explosion after they launched their iphone in  now  looks to be a pivotal year to get in on another emerging technology expected to rock the market demand could soar from almost nothing to  billion by  reports suggest it could save  million lives per decade which could in turn save  billion in us healthcare costsread morea bonus zacks special report names this breakthrough and the  best stocks to exploit it like apple in  these companies are already strong and coiling for potential megagains click to see them right now we are reissuing this article to correct a mistake the original article issued may   should no longer be relied uponwant the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free report click for free quintiles transitional holdings inc q stock analysis report  click for free luminex corporation lmnx stock analysis report  click for free inogen inc ingn stock analysis report  click for free edwards lifesciences corporation ew stock analysis report  to read this article on zackscom click here zacks investment researchreblogsharetweetsharerecently viewedyour list is emptywhat to read nextchevron corporation cvx stock is a wash but i wouldn’t sell it shortinvestorplacezuckerberg wifes ambitious secret finally exposedunewzmesponsoredis ford motor company f stock a buy after its blowout q earningsinvestorplaceidex iex beats on q earnings  revenues raises viewzacksenergy to drive q earnings will etfs reboundzacksthis will be in everyones household by banyan hillsponsoredsean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insidertrump’s unwitting legacy could be universal health coverageyahoo financeamazon wobble ripples across world stock marketsreutersengineer finds pattern makes millions in stocksmoney morningsponsoredstarbucks is shuttering all of its teavana stores as the retail apocalypse kills off american mallsbusiness insidertwitter is only famous now because of president trump nyse traderyahoo finance videogdp — what you need to know in markets on fridayyahoo financewomen need to carry this device with themsiren songsponsoredwhite house comms director scaramucci im not steve bannon im not trying to suck my own ckbusiness insiderrepublicans kill the border taxyahoo financedemocrats line up to take on ‘putin’s favorite congressman’jerryg dana rohrabacher is a clown he is lucky to have a congressional seat in a state like california but his luck is running out and he will have trump to thank for itjoin the conversation   quintiles ims health to merge in  billion deal  reuters discover thomson reutersfinancialgovernment solutionslegalreuters news agencyrisk management solutionstax  accountingblog answers oninnovation  thomson reutersdirectory of siteslogincontactsupporta year agoquintiles ims health to merge in  billion dealrussiatrumpearningshealthcarecyberriskfutureofmoneyenergyenvironmentsectionsbusinessmarketsworldpoliticstechcommentarybreakingviewsmoneylifepicturesreuters tvdiscover thomson reutersfinancialgovernment solutionslegalreuters news agencyrisk management solutionstax  accountingblog answers oninnovation  thomson reutersdirectory of siteslogincontactsupportfeaturedcyber riskbooming cyber security job market boon for hackersfuture of moneydigital currency startups shrug off sec warning on fund raisingpakistanpakistans pm sharif removed in corruption probepicturesreuters tveditionunited statesafricaamérica latinaعربيargentinabrasilcanadadeutschlandespañafranceindiaitaliaméxicoроссияunited kingdomunited statesdealsmay     am  a year agoquintiles ims health to merge in  billion dealnatalie grover min readreuters  contract medical research provider transnational holdings inc qn will merge with healthcare information company ims health holdings inc imsn in a deal worth about  billion the combined company which will have a market value of nearly  billion will offer drug and medical device makers services ranging from helping run clinical trials to tracking sales once a product has hit the market the deal underscores the growing importance of information technology and data analytics in medical research and comes at a time when pharmaceutical companies are cutting costs by increasingly outsourcing drug development while quintiles is one of the worlds largest contract research provider ims health provides market and sales research services to the healthcare industry the combined company  quintiles ims holdings inc  will be led by ims health chief executive ari bousbib quintiles ceo tom pike will become the vice chairman after the deal ims health shareholders will own about  percent of the new entity while quintiles shareholders will own the rest bousbib said it had become hard to identify patients for trial enrollment and create study design as companies develop treatments for complex and rare diseases by having data at our fingertips  we can significantly improve that process and really change the game bousbib said on a conference call with analysts quintiles will offer  of its shares valuing each ims health share at  based on quintiles monday close quintiles shares were down  percent at  while ims healths shares fell  percent to  the offer values the allstock deal at about  billion based on  million ims diluted shares outstanding as of dec  according to reuters data william blair analysts said initial investor reaction was muted given that neither side was receiving a mergerrelated premium and that integration risks are usually higher in a mergerofequals there is an interesting strategic case to be made for putting quintiles and ims together particularly for latestage postapproval work the analysts wrote in a note the merger expands on an existing research agreement between quintiles and ims related to clinical trials and real world research the deal is expected to add to the combined companys  adjusted earnings ims health was advised by goldman sachs its legal adviser was weil gotshal  manges quintiles financial adviser was barclays its legal advisers were bryan cave llp and smith anderson blount dorsett mitchell  jernigan reporting by natalie grover and ankur banerjee in bengaluru additional reporting by siddharth cavale editing by saumyadeb chakrabarty  narrowbrowserandphonemediumbrowserandportraittabletlandscapetabletmediumwidebrowserwidebrowserandlargermediumbrowserandlandscapetabletmediumwidebrowserandlargerabovephoneportraittabletandaboveaboveportraittabletlandscapetabletandabovelandscapetabletandmediumwidebrowserportraittabletandbelowlandscapetabletandbelowappsnewslettersreuters plusadvertising guidelinescookiesterms of useprivacyall quotes delayed a minimum of  minutes see here for a complete list of exchanges and delays  reuters all rights reserved quintiles ims holdings inc  overview skip to main content no logo about us investors careers contact us browse solutions transform clinical development create commercial value lead with realworld insights innovate with technology our difference about us investors careers contact us nyse q    view details volume   minute delay july   investors quintilesims helps to improve healthcare worldwide by providing a broad range of professional services information technology and partnering solutions to the pharmaceutical services biotechnology and healthcare industries overview around the world healthcare stakeholders are working to improve realworld patient outcomes through treatment innovations care provision and access to healthcare for the information technology and service solutions they need to drive new insights and approaches they count on quintilesims with a global team of  we harness insights commercial and scientific depth and executional expertise to empower clients to achieve some of their most important goals improving clinical scientific and commercial results realizing the full potential of innovations and ultimately driving healthcare forward from pipeline to portfolio to population health™ transformational partner to healthcare helped developed or commercializedof the top  topselling products of  kdata feeds and k data suppliers bbillion healthcare transactions processed annually therapeutic centers of excellence coverage of global pharma sales rd platform with data spanning  clinical investigators  indications and  therapeutic areas  million anonymous longitudinal patient journeys for realworld insights  clinical educators   medical doctors   phds   experts in healthcare informatics recent news jul colleen goggins joins quintilesims board of directors pdf format download opens in new window jul quintilesims to announce secondquarter  results on august   pdf format download opens in new window jun quintilesims to participate in william blair growth stock conference on june   pdf format download opens in new window all news upcoming events upcoming events past events aug  am est q  quintilesims earnings conference call add to apple calendar add to google calendar add to microsoft outlook add to icalendar webcast opens in new window view historical events our difference investor toolkit print this page email alerts email this page ir contacts rss feeds sign up for our investor alerts email address  mailing lists  press releases sec filings presentation events eod stock quote annual report   enter the code shown above  investor contact  wooster heights road danbury connecticut  usa tel     emperor boulevard durham north carolina  usa tel    email irquintilesimscom transform clinical development create commercial value lead with realworld insights innovate with technology our difference transform clinical development create commercial value lead with realworld insights innovate with technology our difference about us investors careers contact us privacy statement terms of use suppliers imshealthcom quintilescom twitter linkedin copyright  quintilesims all rights reserved twitter linkedin powered by q inc  opens in new window